Resolving a paradox: antidepressants, neuroinflammation, and neurodegeneration
Ravi Philip Rajkumar
Exploration of Neuroprotective Therapy ›› 2024, Vol. 4 ›› Issue (1) : 11 -37.
Depression is a known risk factor for dementia. Antidepressants are the most commonly used treatment for this condition, and are effective in at least half to two-thirds of cases. Extensive evidence from in vitro and animal models suggests that antidepressants have anti-inflammatory and neuroprotective properties. These effects have been shown to reduce the oxidative damage, amyloid aggregation, and expression of pro-inflammatory genes associated with animal models of neurodegenerative disorders. However, longitudinal research in humans has shown that antidepressants do not protect against dementia, and may even be associated with a risk of cognitive deterioration over time in older adults. The contrast between two sets of findings represents a paradox of significant clinical and public health significance, particularly when treating depression in late life. This review paper attempts to resolve this paradox by critically reviewing the medium- and long-term effects of antidepressants on peripheral immune-inflammatory responses, infection risk, gut microbiota, and neuroendocrine responses to stress, and how these effects may influence the risk of neurodegeneration. Briefly stated, it is possible that the peripheral actions of antidepressant medications may antagonize their beneficial effects against neuroinflammation. The implications of these findings are then explored with a particular focus on the development and testing of multimodal neuroprotective and anti-inflammatory treatments that could reduce the risk of Alzheimer’s and related dementias in patients suffering from depression.
Antidepressants / neuroinflammation / neurodegeneration / Alzheimer’s disease / cytokines / infection / gut-brain axis / hypothalamic-pituitary-adrenal axis
| [1] |
|
| [2] |
GBD 2019 Dementia Forecasting Collaborators. Estimation of the global prevalence of dementia in 2019 and forecasted prevalence in 2050: an analysis for the Global Burden of Disease Study 2019. Lancet Public Health. 2022; 7: e105-25. |
| [3] |
|
| [4] |
|
| [5] |
|
| [6] |
|
| [7] |
|
| [8] |
|
| [9] |
Zhao Q, Xiang H, Cai Y, |
| [10] |
|
| [11] |
|
| [12] |
|
| [13] |
|
| [14] |
|
| [15] |
|
| [16] |
|
| [17] |
|
| [18] |
|
| [19] |
|
| [20] |
|
| [21] |
|
| [22] |
|
| [23] |
|
| [24] |
Pomara N, Bruno D, |
| [25] |
|
| [26] |
|
| [27] |
World Health Organization. Depression and other common mental disorders: global health estimates. Geneva: The Organization; 2017. |
| [28] |
GBD 2019 Mental Disorders Collaborators. Global, regional, and national burden of 12 mental disorders in 204 countries and territories, 1990-2019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet Psychiatry. 2022; 9: 137-50. |
| [29] |
|
| [30] |
Gartlehner G, Dobrescu A, Chapman A, Toromanova A, Emprechtinger R, Persad E, |
| [31] |
|
| [32] |
|
| [33] |
|
| [34] |
|
| [35] |
Blier P. Neurobiology of depression and mechanism of action of depression treatments. J Clin Psychiatry. 2016; 77: e319. |
| [36] |
Khushboo, |
| [37] |
|
| [38] |
Tizabi Y. Duality of antidepressants and neuroprotectants. Neurotox Res. 2016; 30: 1-13. |
| [39] |
|
| [40] |
|
| [41] |
|
| [42] |
|
| [43] |
Mariani N, Everson J, |
| [44] |
|
| [45] |
Harrison NA. Brain structures implicated in inflammation-associated depression. Curr Top Behav Neurosci. 2017; 31: 221-48. |
| [46] |
|
| [47] |
|
| [48] |
|
| [49] |
Dinan TG. Inflammatory markers in depression. Curr Opin Psychiatry. 2009; 22: 32-6. |
| [50] |
|
| [51] |
|
| [52] |
|
| [53] |
|
| [54] |
|
| [55] |
|
| [56] |
|
| [57] |
|
| [58] |
|
| [59] |
|
| [60] |
|
| [61] |
|
| [62] |
|
| [63] |
|
| [64] |
|
| [65] |
|
| [66] |
|
| [67] |
|
| [68] |
|
| [69] |
|
| [70] |
|
| [71] |
|
| [72] |
|
| [73] |
|
| [74] |
|
| [75] |
|
| [76] |
|
| [77] |
|
| [78] |
|
| [79] |
Chanmanee T, Wongpun J, Tocharus C, Govitrapong P, |
| [80] |
|
| [81] |
|
| [82] |
|
| [83] |
|
| [84] |
|
| [85] |
|
| [86] |
Reddy AP, Yin X, Sawant N, Reddy PH. Protective effects of antidepressant citalopram against abnormal APP processing and amyloid beta-induced mitochondrial dynamics, biogenesis, mitophagy and synaptic toxicities in Alzheimer’s disease. Hum Mol Genet. 2021; 30: 847-64. |
| [87] |
|
| [88] |
|
| [89] |
|
| [90] |
|
| [91] |
|
| [92] |
|
| [93] |
|
| [94] |
|
| [95] |
|
| [96] |
|
| [97] |
|
| [98] |
|
| [99] |
|
| [100] |
|
| [101] |
|
| [102] |
|
| [103] |
|
| [104] |
|
| [105] |
|
| [106] |
|
| [107] |
|
| [108] |
|
| [109] |
|
| [110] |
|
| [111] |
|
| [112] |
|
| [113] |
|
| [114] |
|
| [115] |
|
| [116] |
|
| [117] |
|
| [118] |
|
| [119] |
|
| [120] |
|
| [121] |
|
| [122] |
|
| [123] |
|
| [124] |
|
| [125] |
|
| [126] |
|
| [127] |
|
| [128] |
|
| [129] |
|
| [130] |
|
| [131] |
|
| [132] |
|
| [133] |
|
| [134] |
|
| [135] |
|
| [136] |
|
| [137] |
|
| [138] |
|
| [139] |
|
| [140] |
|
| [141] |
|
| [142] |
|
| [143] |
|
| [144] |
|
| [145] |
|
| [146] |
|
| [147] |
Schneider E, Doll JPK, Schweinfurth N, Kettelhack C, Schaub AC, Yamanbaeva G, |
| [148] |
Tian P, Chen Y, Zhu H, Wang L, Qian X, Zou R, |
| [149] |
|
| [150] |
Ross K. Psychobiotics: Are they the future intervention for managing depression and anxiety? A literature review. Explore (NY). 2023; 19: 669-80. |
| [151] |
Mitrea L, |
| [152] |
|
| [153] |
|
| [154] |
|
| [155] |
|
| [156] |
|
| [157] |
|
| [158] |
|
| [159] |
|
| [160] |
|
| [161] |
Ait Chait Y, Mottawea W, Tompkins TA, |
| [162] |
|
| [163] |
|
| [164] |
|
| [165] |
|
| [166] |
Zannas AS. Gene-environment interactions in late life: linking psychosocial stress with brain aging. Curr Neuropharmacol. 2018; 16: 327-33. |
| [167] |
|
| [168] |
|
| [169] |
Song H, Sieurin J, Wirdefeldt K, Pedersen NL, Almqvist C, Larsson H, |
| [170] |
|
| [171] |
|
| [172] |
|
| [173] |
|
| [174] |
|
| [175] |
|
| [176] |
|
| [177] |
|
| [178] |
|
| [179] |
|
| [180] |
|
| [181] |
|
| [182] |
|
| [183] |
|
| [184] |
|
| [185] |
|
| [186] |
|
| [187] |
|
| [188] |
Nikisch G, |
| [189] |
|
| [190] |
|
| [191] |
|
| [192] |
|
| [193] |
|
| [194] |
|
| [195] |
|
| [196] |
|
| [197] |
|
| [198] |
|
| [199] |
|
| [200] |
|
| [201] |
|
| [202] |
|
| [203] |
|
| [204] |
|
| [205] |
|
| [206] |
|
| [207] |
|
| [208] |
|
| [209] |
|
| [210] |
|
| [211] |
Minuti A, Brufani F, Menculini G, Moretti P, |
| [212] |
|
| [213] |
Minichino A, Preston T, Fanshawe JB, Fusar-Poli P, McGuire P, Burnet PWJ, |
| [214] |
|
| [215] |
|
| [216] |
|
| [217] |
|
| [218] |
|
| [219] |
Di Bona D, Plaia A, Vasto S, Cavallone L, Lescai F, Franceschi C, |
| [220] |
|
| [221] |
Köhler O, Benros ME, |
| [222] |
Rios AC, Maurya PK, Pedrini M, Zeni-Graiff M, Asevedo E, Mansur RB, |
/
| 〈 |
|
〉 |